SEARCH

SEARCH BY CITATION

References

  • Abu-Duhier, F.M., Goodeve, A.C., Wilson, G.A., Gari, M.A., Peake, I.R., Rees, D.C., Vandenberghe, E.A., Winship, P.R. & Reilly, J.T. (2000) FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. British Journal of Haematology, 111, 190195.
  • Abu-Duhier, F.M., Goodeve, A.C., Wilson, G.A., Care, R.S., Peake, I.R. & Reilly, J.T. (2001a) Genomic structure of human FLT3: implications for mutational analysis. British Journal of Haematology, 113, 10761077.
  • Abu-Duhier, F.M., Goodeve, A.C., Wilson, G.A., Care, R.S., Peake, I.R. & Reilly, J.T. (2001b) Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. British Journal of Haematology, 113, 983988.
  • Agnes, F., Shamoon, B., Dina, C., Rosnet, O., Birnbaum, D. & Galibert, F. (1994) Genomic structure of the downstream part of the human FLT3 gene: exon/intron structure conservation among genes encoding receptor tyrosine kinases (RTK) of subclass III. Gene, 145, 283288.
  • Armstrong, S.A., Staunton, J.E., Silverman, L.B., Pieters, R., Den Boer, M.L., Minden, M.D., Sallan, S.E., Lander, E.S., Golub, T.R. & Korsmeyer, S.J. (2002) MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nature Genetics, 30, 4147.
  • Arrigoni, P., Beretta, C., Silvestri, D., Rossi, V., Rizzari, C., Valsecchi, M.G., Cazzaniga, G. & Biondi, A. (2003) FLT3 internal tandem duplication in childhood acute myeloid leukaemia: association with hyperleucocytosis in acute promyelocytic leukaemia. British Journal of Haematology, 120, 8992.
  • Birg, F., Courcoul, M., Rosnet, O., Bardin, F., Pebusque, M.J., Marchetto, S., Tabilio, A., Mannoni, P. & Birnbaum, D. (1992) Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood, 80, 25842593.
  • Birkenkamp, K.U., Geugien, M., Lemmink, H.H., Kruijer, W. & Vellenga, E. (2001) Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. Leukemia, 15, 19231931.
  • Bloomfield, C.D., Goldman, A., Hassfeld, D. & De La Chapelle, A. (1984) Fourth International Workshop on Chromosomes in Leukemia 1982: clinical significance of chromosomal abnormalities in acute nonlymphoblastic leukemia. Cancer Genetics and Cytogenetics, 11, 332350.
  • Boissel, N., Cayuela, J.M., Preudhomme, C., Thomas, X., Grardel, N., Fund, X., Tigaud, I., Raffoux, E., Rousselot, P., Sigaux, F., Degos, L., Castaigne, S., Fenaux, P. & Dombret, H. (2002) Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia, 16, 16991704.
  • Bowen, D.T., Frew, M.E., Siannis, F., Gale, R.E., Wheatley, K., Groves, M.J., Talathi, J., Langabeer, S.E., Kottaridis, P.D., Burnett, A.K. & Linch, D.C. (2002) NRAS mutation in acute myeloid leukaemia; new insights into mutation spectrum, frequency within cytogenetic subgroups and clonal size. In: Proceedings from XIII Czech and Slovak Haematology and Transfusion Congress, Prague.
  • Burnett, A.K. (2002) Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation? – an adult treater's view. British Journal of Haematology, 118, 357364.
  • Burnett, A.K., Grimwade, D., Solomon, E., Wheatley, K. & Goldstone, A.H. (1999) Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood, 93, 41314143.
  • Carow, C.E., Levenstein, M., Kaufmann, S.H., Chen, J., Amin, S., Rockwell, P., Witte, L., Borowitz, M.J., Civin, C.I. & Small, D. (1996) Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood, 87, 10891096.
  • Deguchi, K. & Gilliland, D.G. (2002) Cooperativity between mutations in tyrosine kinases and in hematopoietic transcription factors in AML. Leukemia, 16, 740744.
  • Dehmel, U., Zaborski, M., Meierhoff, G., Rosnet, O., Birnbaum, D., Ludwig, W.D., Quentmeier, H. & Drexler, H.G. (1996) Effects of FLT3 ligand on human leukemia cells. I. Proliferative response of myeloid leukemia cells. Leukemia, 10, 261270.
  • Drexler, H.G. (1996) Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia, 10, 588599.
  • Druker, B.J. & Lydon, N.B. (2000) Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. Journal of Clinical Investigation, 105, 37.
  • Fenski, R., Flesch, K., Serve, S., Mizuki, M., Oelmann, E., Kratz-Albers, K., Kienast, J., Leo, R., Schwartz, S., Berdel, W.E. & Serve, H. (2000) Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells. British Journal of Haematology, 108, 322330.
  • Frohling, S., Schlenk, R.F., Breitruck, J., Benner, A., Kreitmeier, S., Tobis, K., Dohner, H. & Dohner, K. (2002) Prognostic significance of activating FLT3 mutations in younger adults (16–60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood, 100, 43724380.
  • Gallagher, R.E., Lee, S.J., Sankoorikal, B.-J., Wiernik, P.H. & Tallman, M.S. (2002) Independent prognostic significance of FLT3 internal tandem duplication (ITD) mutations in acute promyelocytic leukemia (APL) patients treated on ECOG protocol E2491. Blood, 100, 326a.
  • Gilliland, D.G. & Griffin, J.D. (2002) The roles of FLT3 in hematopoiesis and leukemia. Blood, 100, 15321542.
  • Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A. & Goldstone, A. (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood, 92, 23222333.
  • Hannum, C., Culpepper, J., Campbell, D., McClanahan, T., Zurawski, S., Bazan, J.F., Kastelein, R., Hudak, S., Wagner, J., Mattson, J., Luh, J., Duda, G., Martina, N., Peterson, D., Menon, S., Shanafelt, A., Muench, M., Keiner, G., Namikawa, R., Rennick, D., Roncarolo, M.G., Zlotnik, A., Rosnet, O., Dubreuil, P., Birnbaum, D. & Lee, F. (1994) Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature, 368, 643648.
  • Harris, N.L., Jaffe, E.S., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J., Lister, T.A. & Bloomfield, C.D. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. Journal of Clinical Oncology, 17, 38353849.
  • Hawley, T.S., Fong, A.Z., Griesser, H., Lyman, S.D. & Hawley, R.G. (1998) Leukemic predisposition of mice transplanted with gene-modified hematopoietic precursors expressing flt3 ligand. Blood, 92, 20032011.
  • Hayakawa, F., Towatari, M., Kiyoi, H., Tanimoto, M., Kitamura, T., Saito, H. & Naoe, T. (2000) Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene, 19, 624631.
  • Heyworth, C.M., Dexter, T.M., Kan, O. & Whetton, A.D. (1990) The role of hemopoietic growth factors in self-renewal and differentiation of IL-3-dependent multipotential stem cells. Growth Factors, 2, 197211.
  • Horiike, S., Yokota, S., Nakao, M., Iwai, T., Sasai, Y., Kaneko, H., Taniwaki, M., Kashima, K., Fujii, H., Abe, T. & Misawa, S. (1997) Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia. Leukemia, 11, 14421446.
  • Hovland, R., Gjertsen, B.T. & Bruserud, O. (2002) Acute myelogenous leukemia with internal tandem duplication of the Flt3 gene appearing or altering at the time of relapse: a report of two cases. Leukemia and Lymphoma, 43, 20272029.
  • Ishii, E., Zaitsu, M., Ihara, K., Hara, T. & Miyazaki, S. (1999) High expression but no internal tandem duplication of FLT3 in normal hematopoietic cells. Pediatric Hematology and Oncology, 16, 437441.
  • Iwai, T., Yokota, S., Nakao, M., Okamato, T., Taniwaki, M., Onodera, N., Watanabe, A., Kikuta, A., Tanaka, A., Asami, K., Sekine, I., Mugishima, H., Nishimura, Y., Koizumi, S., Horikoshi, Y., Mimaya, J., Ohta, S., Nishikawa, K., Iwai, A., Shimokawa, T., Nakayama, M., Kawakami, K., Gushiken, T., Hyakuna, N., Katano, N., Tsurusawa, M., & Fujimoto, T. (1999) Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. The Children's Cancer and Leukemia Study Group, Japan. Leukemia, 13, 3843.
  • Jamal, R., Taketani, T., Taki, T., Bessho, F., Hongo, T., Hamaguchi, H., Horiike, S., Taniwaki, M., Hanada, R., Nakamura, H. & Hayashi, Y. (2001) Coduplication of the MLL and FLT3 genes in patients with acute myeloid leukemia. Genes Chromosomes and Cancer, 31, 187190.
  • Kainz, B., Heintel, D., Marculescu, R., Schwarzinger, I., Sperr, W., Le, T., Weltermann, A., Fonatsch, C., Haas, O.A., Mannhalter, C., Lechner, K. & Jaeger, U. (2002) Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8,21) or inv (16). Hematology Journal, 3, 283289.
  • Kelly, L.M., Liu, Q., Kutok, J.L., Williams, I.R., Boulton, C.L. & Gilliland, D.G. (2002a) FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood, 99, 310318.
  • Kelly, L.M., Kutok, J.L., Williams, I.R., Boulton, C.L., Amaral, S.M., Curley, D.P., Ley, T.J. & Gilliland, D.G. (2002b) PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proceedings of the National Academy of Sciences of the USA, 99, 82838288.
  • Kelly, L.M., Yu, J.C., Boulton, C.L., Apatira, M., Li, J., Sullivan, C.M., Williams, I., Amaral, S.M., Curley, D.P., Duclos, N., Neuberg, D., Scarborough, R.M., Pandey, A., Hollenbach, S., Abe, K., Lokker, N.A., Gilliland, D.G. & Giese, N.A. (2002c) CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell, 1, 421432.
  • Kiyoi, H., Naoe, T., Yokota, S., Nakao, M., Minami, S., Kuriyama, K., Takeshita, A., Saito, K., Hasegawa, S., Shimodaira, S., Tamura, J., Shimazaki, C., Matsue, K., Kobayashi, H., Arima, N., Suzuki, R., Morishita, H., Saito, H., Ueda, R. & Ohno, R. (1997) Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia, 11, 14471452.
  • Kiyoi, H., Towatari, M., Yokota, S., Hamaguchi, M., Ohno, R., Saito, H. & Naoe, T. (1998) Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia, 12, 13331337.
  • Kiyoi, H., Naoe, T., Nakano, Y., Yokota, S., Minami, S., Miyawaki, S., Asou, N., Kuriyama, K., Jinnai, I., Shimazaki, C., Akiyama, H., Saito, K., Oh, H., Motoji, T., Omoto, E., Saito, H., Ohno, R. & Ueda, R. (1999) Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood, 93, 30743080.
  • Kiyoi, H., Ohno, R., Ueda, R., Saito, H. & Naoe, T. (2002) Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene, 21, 25552563.
  • Kondo, M., Horibe, K., Takahashi, Y., Matsumoto, K., Fukuda, M., Inaba, J., Kato, K., Kojima, S. & Matsuyama, T. (1999) Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia. Medical and Pediatric Oncology, 33, 525529.
  • Kottaridis, P.D., Gale, R.E., Frew, M.E., Harrison, G., Langabeer, S.E., Belton, A.A., Walker, H., Wheatley, K., Bowen, D.T., Burnett, A.K., Goldstone, A.H. & Linch, D.C. (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood, 98, 17521759.
  • Kottaridis, P.D., Gale, R.E., Langabeer, S.E., Frew, M.E., Bowen, D.T. & Linch, D.C. (2002a) Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood, 100, 23932398.
  • Kottaridis, P.D., Gale, R.E., Holt, M., Wheatley, K., Goldstone, A.H., Burnett, A.K. & Linch, D.C. (2002b) Consolidation of AML therapy with autograft and allograft procedures does not negate the poor prognostic impact of FLT3 internal tandem duplications: results from the UK MRC AML10 and 12 trials. Blood, 100, 75a.
  • Levis, M., Tse, K.F., Smith, B.D., Garrett, E. & Small, D. (2001) A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood, 98, 885887.
  • Levis, M., Allebach, J., Tse, K.F., Zheng, R., Baldwin, B.R., Smith, B.D., Jones-Bolin, S., Ruggeri, B., Dionne, C. & Small, D. (2002) A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood, 99, 38853891.
  • Liang, D.C., Shih, L.Y., Hung, I.J., Yang, C.P., Chen, S.H., Jiang, T.H., Liu, H.C. & Chang, W.H. (2002) Clinical relevance of internal tandem duplication of the FLT3 gene in childhood acute myeloid leukemia. Cancer, 94, 32923298.
  • Libura, M., Asnafi, V., Tu, A., Tigaud, I., Cymbalista, F., Bennaceur, A.-L., Leboeuf, D., Delabesse, E., Beldjord, K., Solbu, G., Hagemeijer, A., Hermine, O. & Macintyre, E. (2002) Flt3 and MLL internal tandem duplications and topoisomerase II breakages reflect a common category of genotoxic stress: an EORTC study. Blood, 100, 530a.
  • Lyman, S.D. (1995) Biology of flt3 ligand and receptor. International Journal of Hematology, 62, 6373.
  • Mackarehtschian, K., Hardin, J.D., Moore, K.A., Boast, S., Goff, S.P. & Lemischka, I.R. (1995) Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity, 3, 147161.
  • Maroc, N., Rottapel, R., Rosnet, O., Marchetto, S., Lavezzi, C., Mannoni, P., Birnbaum, D. & Dubreuil, P. (1993) Biochemical characterization and analysis of the transforming potential of the FLT3/FLK2 receptor tyrosine kinase. Oncogene, 8, 909918.
  • Meshinchi, S., Woods, W.G., Stirewalt, D.L., Sweetser, D.A., Buckley, J.D., Tjoa, T.K., Bernstein, I.D. & Radich, J.P. (2001) Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood, 97, 8994.
  • Mesters, R.M., Padro, T., Bieker, R., Steins, M., Kreuter, M., Goner, M., Kelsey, S., Scigalla, P., Fiedler, W., Buchner, T. & Berdel, W.E. (2001) Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood, 98, 241243.
  • Mizuki, M., Fenski, R., Halfter, H., Matsumura, I., Schmidt, R., Muller, C., Gruning, W., Kratz-Albers, K., Serve, S., Steur, C., Buchner, T., Kienast, J., Kanakura, Y., Berdel, W.E. & Serve, H. (2000) Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood, 96, 39073914.
  • Mizuki, M., Schwaeble, J., Steur, C., Choudhary, C., Agrawal, S., Sargin, B., Steffen, B., Matsumura, I., Kanakura, Y., Boehmer, F.D., Mueller-Tidow, C., Berdel, W.E. & Serve, H. (2003) Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood, 101, 31643173.
  • Nakano, Y., Kiyoi, H., Miyawaki, S., Asou, N., Ohno, R., Saito, H. & Naoe, T. (1999) Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene. British Journal of Haematology, 104, 659664.
  • Nakao, M., Yokota, S., Iwai, T., Kaneko, H., Horiike, S., Kashima, K., Sonoda, Y., Fujimoto, T. & Misawa, S. (1996) Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia, 10, 19111918.
  • Nakao, M., Janssen, J.W., Erz, D., Seriu, T. & Bartram, C.R. (2000) Tandem duplication of the FLT3 gene in acute lymphoblastic leukemia: a marker for the monitoring of minimal residual disease (letter). Leukemia, 14, 522524.
  • Noguera, N.I., Breccia, M., Divona, M., Diverio, D., Costa, V., De Santis, S., Avvisati, G., Pinazzi, M.B., Petti, M.C., Mandelli, F. & Lo Coco, F. (2002) Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia, 16, 21852189.
  • Palumbo, G.A., Tanteri, V., Buglio, D., Guagliardo, P., Romeo, M.A., Di Raimondo, F. & Giustolisi, R. (2002) FLT3-activating mutations in acute promyelocytic leukemia: higher incidence of ITD in BCR3 patients. Blood, 100, 326a.
  • Preudhomme, C., Sagot, C., Boissel, N., Cayuela, J.M., Tigaud, I., De Botton, S., Thomas, X., Raffoux, E., Lamandin, C., Castaigne, S., Fenaux, P. & Dombret, H. (2002) Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood, 100, 27172723.
  • Rombouts, W.J., Blokland, I., Lowenberg, B. & Ploemacher, R.E. (2000) Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia, 14, 675683.
  • Rosnet, O., Mattei, M.G., Marchetto, S. & Birnbaum, D. (1991) Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene. Genomics, 9, 380385.
  • Rosnet, O., Schiff, C., Pebusque, M.J., Marchetto, S., Tonnelle, C., Toiron, Y., Birg, F. & Birnbaum, D. (1993) Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood, 82, 11101119.
  • Sawyers, C.L. (2002) Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell, 1, 413415.
  • Schnittger, S., Kinkelin, U., Schoch, C., Heinecke, A., Haase, D., Haferlach, T., Buchner, T., Wormann, B., Hiddemann, W. & Griesinger, F. (2000) Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia, 14, 796804.
  • Schnittger, S., Schoch, C., Dugas, M., Kern, W., Staib, P., Wuchter, C., Loffler, H., Sauerland, C.M., Serve, H., Buchner, T., Haferlach, T. & Hiddemann, W. (2002a) Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood, 100, 5966.
  • Schnittger, S., Boell, I., Schoch, C., Dugas, M., Kern, W., Sauerland, M.C., Hiddeman, W. & Haferlach, T. (2002b) FLT3D835/I836 point mutations in acute myeloid leukemia: correlation to cytogenetics, cytomorphology, and prognosis in 1229 patients. Blood, 100, 329a.
  • Shih, L.-Y., Kuo, M.-C., Liang, D.-C., Huang, C.-F., Lin, T.-L., Wu, J.-H., Dunn, P. & Lai, C.-L. (2002a) FLT3 mutations in acute promeylocytic leukemia: high association with type-S PML/RARα isoform but without prognostic impact. Blood, 100, 326a.
  • Shih, L.Y., Huang, C.F., Wu, J.H., Lin, T.L., Dunn, P., Wang, P.N., Kuo, M.C., Lai, C.L. & Hsu, H.C. (2002b) Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood, 100, 23872392.
  • Spiekermann, K., Bagrintseva, K., Schoch, C., Haferlach, T., Hiddemann, W. & Schnittger, S. (2002) A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia. Blood, 100, 34233425.
  • Spiekermann, K., Dirschinger, R.J., Schwab, R., Bagrintseva, K., Faber, F., Buske, C., Schnittger, S., Kelly, L.M., Gilliland, D.G. & Hiddemann, W. (2003) The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3. Blood, 101, 14941504.
  • Steudel, C., Wermke, M., Schaich, M., Schaekel, U., Illmer, T., Ehninger, G. & Thiede, C. (2002) MLL PTD and FLT3 ITD mutations are associated with different clinical features in adult patients with AML. Blood, 100, 747a.
  • Stirewalt, D.L., Kopecky, K.J., Meshinchi, S., Appelbaum, F.R., Slovak, M.L., Willman, C.L. & Radich, J.P. (2001) FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood, 97, 35893595.
  • Stone, R.M., Klimek, V., DeAngelo, D.J., Nimer, S., Estey, E., Galinsky, I., Neuberg, D., Yap, A., Fox, E.A., Gilliland, D.G. & Griffin, J. (2002) PKC412, an oral FLT3 inhibitor, has activity in mutant FLT3 acute myeloid leukemia (AML): a phase II clinical trial. Blood, 100, 86a.
  • Strout, M.P., Marcucci, G., Bloomfield, C.D. & Caligiuri, M.A. (1998) The partial tandem duplication of ALL1 (MLL) is consistently generated by Alu-mediated homologous recombination in acute myeloid leukemia. Proceedings of the National Academy of Sciences of the USA, 95, 23902395.
  • Taketani, T., Taki, T., Ishii, E., Hanada, R., Tsuchida, M., Sugita, K., Sugita, K. & Hayashi, Y. (2002) FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL gene rearrangement. Blood, 100, 740a.
  • Tallman, M.S., Andersen, J.W., Schiffer, C.A., Appelbaum, F.R., Feusner, J.H., Ogden, A., Shepherd, L., Willman, C., Bloomfield, C.D., Rowe, J.M. & Wiernik, P.H. (1997) All-trans-retinoic acid in acute promyelocytic leukemia. New England Journal of Medicine, 337, 10211028.
  • Teller, S., Kramer, D., Bohmer, S.A., Tse, K.F., Small, D., Mahboobi, S., Wallrapp, C., Beckers, T., Kratz-Albers, K., Schwable, J., Serve, H. & Bohmer, F.D. (2002) Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3. Leukemia, 16, 15281534.
  • Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schakel, U., Platzbecker, U., Wermke, M., Bornhauser, M., Ritter, M., Neubauer, A., Ehninger, G. & Illmer, T. (2002a) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood, 99, 43264335.
  • Thiede, C., Steudel, C., Illmer, T., Schaich, M., Schaekel, U., Bornhaeuser, M. & Ehninger, G. (2002b) Treatment of FLT3-ITD positive acute myelogenous leukemia with allogeneic and autologous stem cell transplantation – results in 175 patients. Blood, 100, 747a.
  • Tse, K.F., Novelli, E., Civin, C.I., Bohmer, F.D. & Small, D. (2001) Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia, 15, 10011010.
  • Tse, K.F., Allebach, J., Levis, M., Smith, B.D., Bohmer, F.D. & Small, D. (2002) Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor. Leukemia, 16, 20272036.
  • Weisberg, E., Boulton, C., Kelly, L.M., Manley, P., Fabbro, D., Meyer, T., Gilliland, D.G. & Griffin, J.D. (2002) Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell, 1, 433443.
  • Wheatley, K., Burnett, A.K., Goldstone, A.H., Gray, R.G., Hann, I.M., Harrison, C.J., Rees, J.K., Stevens, R.F. & Walker, H. (1999) A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. British Journal of Haematology, 107, 6979.
  • Whitman, S.P., Archer, K.J., Feng, L., Baldus, C., Becknell, B., Carlson, B.D., Carroll, A.J., Mrozek, K., Vardiman, J.W., George, S.L., Kolitz, J.E., Larson, R.A., Bloomfield, C.D. & Caligiuri, M.A. (2001) Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Research, 61, 72337239.
  • Xu, F., Taki, T., Yang, H.W., Hanada, R., Hongo, T., Ohnishi, H., Kobayashi, M., Bessho, F., Yanagisawa, M. & Hayashi, Y. (1999) Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. British Journal of Haematology, 105, 155162.
  • Xu, F., Taki, T., Eguchi, M., Kamada, N., Ishii, E., Endo, M. & Hayashi, Y. (2000) Tandem duplication of the FLT3 gene is infrequent in infant acute leukemia. Japan Infant Leukemia Study Group (letter). Leukemia, 14, 945947.
  • Yaish, P., Gazit, A., Gilon, C. & Levitzki, A. (1988) Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science, 242, 933935.
  • Yamamoto, Y., Kiyoi, H., Nakano, Y., Suzuki, R., Kodera, Y., Miyawaki, S., Asou, N., Kuriyama, K., Yagasaki, F., Shimazaki, C., Akiyama, H., Saito, K., Nishimura, M., Motoji, T., Shinagawa, K., Takeshita, A., Saito, H., Ueda, R., Ohno, R. & Naoe, T. (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood, 97, 24342439.
  • Yee, K.W., O'Farrell, A.M., Smolich, B.D., Cherrington, J.M., McMahon, G., Wait, C.L., McGreevey, L.S., Griffith, D.J. & Heinrich, M.C. (2002) SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood, 100, 29412949.
  • Yokota, S., Kiyoi, H., Nakao, M., Iwai, T., Misawa, S., Okuda, T., Sonoda, Y., Abe, T., Kahsima, K., Matsuo, Y. & Naoe, T. (1997) Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia, 11, 16051609.
  • Zheng, R., Friedman, A.D. & Small, D. (2002) Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations. Blood, 100, 41544161.
  • Zhao, M., Kiyoi, H., Yamamoto, Y., Ito, M., Towatari, M., Omura, S., Kitamura, T., Ueda, R., Saito, H. & Naoe, T. (2000) In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor. Leukemia, 14, 374378.
  • Zwaan, C.M., Meshinchi, S., Radich, J.P., Veerman, A.J.P., Huismans, D.R., Kaspers, G.J., Hahlen, K., Zimmermann, M., Reinhart, D., Harbott, J., Creutzig, U., Kaspars, G.J.L. & Greisinger, F. (2002) Flt3 internal tandem duplication in childhood acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood, 100, 33a.